Form D · Biotechnology
Arsenal Biosciences, Inc.
South San Francisco, CA · CIK 0001945638
Offering snapshot reported Sep 4, 2024 · SEC filing
- Reported sold
- $325M Offering amount: $325M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 9, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 4, 2024 | Initial | $325,352,578 | No comparison | 26 | SEC filing |
| Sep 9, 2022 | Initial | $32,999,954 | No comparison | 9 | SEC filing |
| Sep 9, 2022 | Initial | $220,806,682 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-523129
Series C Preferred Stock and the respective common stock issuable upon conversion thereof.
Source: Form D, filed Sep 4, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| James Ahlers | Executive |
| Valentin Barsan | Director |
| Brook Byers | Director |
| Kenneth Drazan | Director, Executive |
| Matthew Fust | Director |
| Margaret Nibbi | Executive |
| Sean Parker | Director |
| Irene Pleasure | Executive |
| Beth Seidenberg | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
329 Oyster Point Blvd
South San Francisco, CA, 94080
South San Francisco, CA, 94080